Naver is stepping up to expand the healthcare ecosystem based on artificial intelligence (AI) technology.
Naver recently noted that it held the 'Naver-J&PMedi Comprehensive Business Agreement Ceremony in the Field of Digital Healthcare' on the 13th.
J&PMedi provides a clinical trial data platform for pharmaceuticals, biosciences, and medical device corporations and supports services such as clinical trial contract research organization (CRO) services, investment support, and licensing consulting. In addition to consulting on establishing strategies for new drug and medical device technology transfers and contract negotiations, it offers a variety of functions through its self-developed platform, which includes international standard-based clinical data management, operation, clinical trials, and quality management.
Naver plans to closely collaborate with J&PMedi to achieve management of clinical trial data, a national strategic asset, and technological independence. Furthermore, by combining AI technology, it aims to implement the digital clinical trial capabilities necessary for global expansion and strives to build digital transformation infrastructure across the entire domestic healthcare ecosystem.
Meanwhile, in this investment round, TBT participated as a co-investor as a new shareholder. Naver and TBT made strategic investments in J&PMedi through this round.